PIK3CA and breast cancer: In BELLE-3, the subgroup of PIK3CA-mutated BC seemed to derive a higher benefit from buparlisib: 4.7 versus 1.4 months, with a better HR of 0.39 (95% CI 0.23–0.65) than in the overall cohort.